2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

4:30PM-6:00PM: Abstract Number: 2861

Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)

4:30PM-6:00PM: Abstract Number: 2893

Clinical Outcomes and Response to Anti-Thrombotic Treatment Among Patients with Concomitant Lupus Nephritis and Thrombotic Microangiopathy: A Multicenter Cohort Study

5T111 ACR Abstract: SLE–Clinical IV: Clinical Outcomes (2892–2897)

4:30PM-6:00PM: Abstract Number: 2874

Comparison of Missing Data Reporting and Handling in Randomized Controlled Trials of Rheumatoid Arthritis Drug Therapy: A Snapshot Ten Years Apart

5T109 ACR Abstract: RA–Treatments V: Beyond Individual Compounds (2874–2879)

4:30PM-6:00PM: Abstract Number: 2871

Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis

5T108 ACR Abstract: RA–DX, Manifestations, & Outcomes V: Outcomes Measures (2868–2873)

4:30PM-6:00PM: Abstract Number: 2888

Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis

5T112 ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Tx of PsA & Peripheral SpA (2886–2891)

4:30PM-6:00PM: Abstract Number: 2884

Correlation between Salivary Gland Ultrasonography, Minor Salivary Gland Histhopatology and Sialometry: Towards a Composite Assessment of Salivary Gland Involvement in Primary Sjögren’s Syndrome

5T110 ACR Abstract: Sjögren's Syndrome–Basic & Clinical Science (2880–2885)

4:30PM-6:00PM: Abstract Number: 2860

Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry

5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)

4:30PM-6:00PM: Abstract Number: 2856

Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the Acr’s RISE Registry

5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)

4:30PM-6:00PM: Abstract Number: 2859

Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?

5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)

4:30PM-6:00PM: Abstract Number: 2890

Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study

5T112 ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Tx of PsA & Peripheral SpA (2886–2891)

4:30PM-6:00PM: Abstract Number: 2895

Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial

5T111 ACR Abstract: SLE–Clinical IV: Clinical Outcomes (2892–2897)

4:30PM-6:00PM: Abstract Number: 2867

Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)

4:30PM-6:00PM: Abstract Number: 2891

Eligibility Criteria for TNFi Therapy in Axial Spa: Going Beyond Basdai

5T112 ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Tx of PsA & Peripheral SpA (2886–2891)

4:30PM-6:00PM: Abstract Number: 2852

Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus

5T105 ACR Abstract: Innate Immunity (2850–2855)

4:30PM-6:00PM: Abstract Number: 2855

Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira

5T105 ACR Abstract: Innate Immunity (2850–2855)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].